回盛生物(300871) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 reached ¥356,249,707.67, representing a 47.03% increase year-over-year[2] - Net profit attributable to shareholders was ¥4,220,375.20, a significant increase of 513.52% compared to the same period last year[2] - Basic earnings per share for Q3 2024 were ¥0.03, reflecting a 400.00% increase year-over-year[2] - Total operating revenue for Q3 2024 reached CNY 792.55 million, an increase of 14.6% compared to CNY 691.39 million in the same period last year[17] - The net profit for Q3 2024 was a loss of CNY 47.62 million, compared to a profit of CNY 14.88 million in the same period last year[19] - The basic earnings per share for Q3 2024 was reported at -CNY 0.29, compared to CNY 0.09 in the previous year[19] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥7,110,643.63, down 87.54% from the previous year[2] - The net cash flow from financing activities was ¥29,649,582.00, a turnaround from a negative cash flow of ¥41,053,633.66 in the previous year[8] - The total cash inflow from operating activities was CNY 727,679,278.47, a decrease of 2.3% compared to CNY 744,551,814.05 in the previous period[20] - The net cash flow from operating activities was CNY 7,110,643.63, significantly down from CNY 57,060,213.12 in the same period last year[20] - Cash inflow from financing activities was CNY 423,425,243.00, an increase of 80.7% compared to CNY 234,000,720.00 in the previous period[21] - The net cash flow from financing activities was CNY 29,649,582.00, a turnaround from -CNY 41,053,633.66 in the same period last year[21] Assets and Liabilities - Total assets as of September 30, 2024, were ¥2,912,533,318.94, a decrease of 2.11% from the end of the previous year[2] - The total assets decreased to CNY 2.91 billion from CNY 2.98 billion, showing a decline in overall asset value[16] - Total liabilities increased slightly to CNY 1.49 billion from CNY 1.47 billion, indicating a stable financial position[16] - The company's equity attributable to shareholders decreased to CNY 1.42 billion from CNY 1.51 billion, reflecting the impact of the net loss[16] Financial Expenses - The company reported a significant increase in financial expenses, totaling ¥32,813,572.34, which is a 140.51% rise compared to the same period last year[6] - The company reported a significant increase in financial expenses, rising to CNY 32.81 million from CNY 13.64 million, primarily due to higher interest costs[17] Fair Value Changes - The fair value changes resulted in a loss of ¥37,453,462.24, a drastic decline of 977.08% year-over-year[7] - The fair value changes resulted in a loss of CNY 37.45 million, contrasting with a gain of CNY 4.27 million in the previous year, indicating volatility in financial assets[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 10,820[9] - Wuhan Tongsheng Investment Co., Ltd. holds 49.95% of shares, totaling 82,800,000 shares, with 6,200,000 shares pledged[9] - The company repurchased 753,600 shares, accounting for 0.45% of the total share capital[10] - The employee stock ownership plan holds 1,635,450 shares, representing 0.99% of the total shares[9] - The top ten shareholders do not include any shareholders participating in margin trading[12] Government Subsidies - The company received government subsidies amounting to ¥7,348,230.15, primarily related to previous years' asset-related subsidies[3] Operating Costs and Expenses - Total operating costs for Q3 2024 were CNY 838.14 million, up from CNY 689.04 million, reflecting a significant increase in operating expenses[17] - Research and development expenses increased to CNY 38.95 million, up from CNY 31.21 million, indicating a focus on innovation[17] Cash and Cash Equivalents - The company's cash and cash equivalents at the end of the reporting period amount to ¥237,278,933.04, down from ¥293,609,731.56 at the beginning of the period[14] - The ending balance of cash and cash equivalents was CNY 139,349,768.58, up from CNY 119,411,165.19 in the previous year[21] Borrowings and Debt Repayments - The company’s short-term borrowings increased by 54.04%, reaching ¥370,179,161.00 during the reporting period[5] - The company received CNY 360,000,000.00 in borrowings, compared to CNY 170,000,000.00 in the previous period, reflecting a significant increase[21] - The company paid CNY 339,620,272.90 in debt repayments, up from CNY 210,000,000.00 in the previous year[21] Tax Payments - The company reported a decrease in tax payments to CNY 23,901,686.77 from CNY 33,238,724.16 in the previous period[20] Future Plans - The company has no plans for new product launches or market expansions mentioned in the report[13]